S Gabrielsen, MD
Surgery · Linton, INNPI 1942324157
Payments from drug & device makers
Across 55 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$133
- Tetraphase Pharmaceuticals, Inc.$108
- Kerecis Limited$75
- Organogenesis Inc.$73
- Misonix Inc$67
- Integra Lifesciences Corporation$57
- plus $425 from 17 others
What the payments were for
- Food & beverage$938100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 7 | $133 |
| Tetraphase Pharmaceuticals, Inc. | 7 | $108 |
| Kerecis Limited | 4 | $75 |
| Organogenesis Inc. | 5 | $73 |
| Misonix Inc | 4 | $67 |
| Integra Lifesciences Corporation | 3 | $57 |
| Johnson & Johnson(2 entities) | 2 | $47 |
| Bioventus LLC | 2 | $46 |
| Tactile Systems Technology Inc | 3 | $42 |
| TELA Bio, Inc. | 2 | $41 |
| Cook Medical LLC | 3 | $41 |
| La Jolla Pharmaceutical Company | 2 | $30 |
| Braintree Laboratories, Inc. | 1 | $22 |
| AbbVie | 1 | $22 |
| GSK | 1 | $19 |
| Medline Industries LP | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Abbott | 1 | $13 |
| Osiris Therapeutics Inc. | 1 | $13 |
| Innocoll Pharmaceuticals Limited | 1 | $13 |
| Asensus Surgical, Inc. | 1 | $12 |
How this compares
$938 in reported general payments places this provider in the 40th percentile of 524 surgery providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 34 | $7,776 |
| Lubiprostone | 19 | $2,371 |
| Omeprazole | 70 | $800 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 41 | $127 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $125 |
| Famotidine | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Other surgery in Linton
- Paul SzotekIndianapolis$2.4M
- Lewis JacobsonIndianapolis$761K
- Carlos Gonzalez RendonMunster$275K
- Christian SchmidtIndianapolis$257K
- Anthony ZappiaCarmel$105K
- Jeremy Luedtkela Porte$102K
- Patricia ClarkFort Wayne$82K
- Erica GiblinCarmel$70K
- Paul BowldsGreenwood$69K
- Michael MillerIndianapolis$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.